



# eve investments


AGM PRESENTATION  
November 2018






# Investment Focus


**Eve's vision is to be a vertically integrated Health, Food and Wellness Investment company.**



Investing and owning early growth phase companies with the aim to manage and support their expansion programs.



Identifying products that have unique attributes that compliment existing portfolio investments with growing demand and a global reach/application.



A strong preference for natural, organic and traceable products that strengthen our Delivery platform.




# Our Company Structure





# Meluka Health – Business Structure





# Control Our Own Destiny

## Own the Customer Relationship



## Brand Building



## Leverage Our Assets



Vertically  
Integrated  
Complementary  
Businesses



# Strategic Approach





# Secure Supply Chain



Acquiring Jenbrook gives us over 2,100 acres of organic Melaleuca Tea Tree Plantation of which nearly half is an old growth plantation in its natural state.

This land not only provides Tea Tree oil and extract for distribution direct into the US and Europe and that provide a unique foundation to Meluka Health's product offering via its subsidiaries.







# Establish Brands in Our Home Market



Launched in Australia in May 2018







# Innovate and Develop



**meluka essentials**




Products developed.  
Awaiting final design approval and manufacture.  
Expected to launch in Q1 2019.



## Innovate and Develop *continued*



Meluka Honey has entered an agreement with ASX Listed THC who will be growing cannabis on Jenbrook's organic plantation to use the cannabis as part of its Cannabis Honey product.



A range of versatile family products utilising Australian botanicals.

The initial range includes a Baby head and body wash, a Baby massage oil, Mother's belly massage oil and a Mothers bath soak.

Expected to launch in Q3 of 2019.



# Grow into Global Markets



- Establish roots and brand recognition in our home country.



- Established network via NAP
- Focus will be direct to consumer growth



- Established network via Jenbrook
- Focus will be expanding the Jenbrook growth with Bulk sales



- New Market that will be a priority for all direct to consumer products.



- New Market that will be a priority for all direct to consumer products.







# Momentum is Gathering

## December 2017

- Meluka Health and Meluka Honey companies incorporated on ASIC.

## January 2018

- Meluka Honey establishes hives on Plantation to have production capacity to meet large scale demand.

## March 2018

- Meluka Honey develops initial honey consumer product range.

## April 2018

- Bulk Honey sales launched in the US via Distribution partner Naturally Australian Products Inc.

## May 2018

- Meluka Honey Consumer Products launched in Australia.

## June 2018

- Meluka Essentials develops initial product range.

## July 2018

- Meluka Health enters agreement with THC to grow high grade medicinal cannabis on Robyndale and provide access to this organic certified cannabis for its planned Medicinal cannabis honey.

## August 2018

- Jenbrook Purchased.
- Naturally Australian Products 49% completed.
- Meluka Family initial product range developed.

## November 2018

- Research findings released by Southern Cross University into honey and honeybee health.
- Distribution secured with The Fair Traders in NSW & ACT.



## Current Update

- 🌱 Distribution and Sales of Pre-meal drink for diabetes into China via agreement with Eagle Health (ASX: EHH) has commenced.
- 🌱 Eagle Health have invested \$3.1m and committed a further \$5.7m for factory, warehouse and exhibition centre upgrades including a high speed line for the production of Hutang 1 diabetes product using Omni's licensed technology.
- 🌱 Eagle have advised that they are continuing to work towards its plan to roll out 100 direct stores along the affluent East Coast of China, and are on track and are expected to reach approximately 570 million consumers. These Eagle Health Education and Experience stores will sell Eagle Health's Hutang One diabetes product, Eagle's new range of modern Traditional Chinese Medicine products and a selected range of Australian sourced health products.





## Innovation - Next Steps

- 🌱 Eagle to get CFDA registration as 'Food For Special Medical Purposes' in China.
- 🌱 Eagle to continue China roll out of existing Chinese distribution with a move to 7 seven stores on the way to reach 100 stores.
- 🌱 New markets targeted in Asia to launch via a similar structured licensing model.



**鹰君健康控股**  
EAGLE HEALTH HOLDINGS LIMITED

ASX:EHH







# eve investments

## Summary

- 🦋 The Health food and wellness sector is growing rapidly particularly into Asian Markets.
- 🦋 Eve is well exposed to the sector via it's investments and anticipated growth of the Meluka Brand.
- 🦋 By controlling all aspects of the supply chain, Eve's investments are able to adapt and tailor products to meet this demand.
- 🦋 Revenue generation ramping in its business investments

# DISCLAIMER



The information contained in this presentation is not financial product advice. The presentation is for information purposes and is of a general and summary nature only. It does not constitute an offer. EVE Investments Limited (EVE) gives no warranties in relation to the statements and information in this presentation. Investors should seek appropriate advice on their own objectives, financial situation and needs.



This presentation contains certain statements which may constitute “forward-looking statements”. Such statements are only predictions and are subject to inherent risks and uncertainties which could cause actual values, performance or achievements to differ materially from those expressed, implied or projected in any forward looking statements.



EVE disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise. Investors are cautioned that forward-looking statements are not guarantees of future performance and investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.



This presentation does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or commitment or investment decision relating to any securities in the Company. Any decision regarding any proposed subscription for securities in the Company must be made solely on the basis of information on the Company that is publicly available.